HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BRISTOL-MYERS SQUIBB EXPANDING SALON HAIR CARE WITH MATRIX ESSENTIALS

This article was originally published in The Rose Sheet

Executive Summary

BRISTOL-MYERS SQUIBB EXPANDING SALON HAIR CARE WITH MATRIX ESSENTIALS acquisition, the firm announced June 16. With the purchase, BMS will add the VaVoom!, Matrix Essentials and Systeme Biolage professional hair care brands to its sole salon-only line, Logics International. The Matrix Essentials acquisition also will mark BMS's entrance into color cosmetics and will broaden its skin care offerings. Matrix Essentials sells color cosmetics and skin care products under the Matrix name. BMS currently markets the Sea Breeze skin care line and Keri and Lac-Hydrin therapeutic moisturizers. Another large firm that recently bolstered its salon hair care business via acquisition is Cosmair, which bought Redken last June ("The Rose Sheet" June 28, 1993, p. 1).

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel